Hinova Pharmaceuticals Inc., a clinical-stage pharmaceutical company, develops and produces therapeutics for cancers and metabolic syndromes. Its core product i...
Shanghai Composite Nears Positive Territory, Pharmaceutical Stocks Surge, Computing Hardware Stocks Continue to Adjust, HSI Fluctuates Higher, New Consumption Concept Stocks Rebound, POP MART Rises 2%
Shineway Profit Rises Despite Revenue Slump as TCM Sector Resets
HashKey Sets March 2026 Board Meeting to Approve 2025 Final Results
Two major industries' stocks cluster in the gross margin ranking, with 27 stocks having a gross margin exceeding 90% in the first half of the year
The concept of innovative drugs fluctuates and rebounds, JZT hits the limit up
Hinova Pharmaceuticals released its semi-annual performance, with a net loss attributable to the parent company of 61.85 million yuan